United Therapeutics Corporation $UTHR Shares Acquired by Rehmann Capital Advisory Group

Rehmann Capital Advisory Group lifted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 19.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,170 shares of the biotechnology company’s stock after buying an additional 348 shares during the quarter. Rehmann Capital Advisory Group’s holdings in United Therapeutics were worth $624,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Chung Wu Investment Group LLC acquired a new position in United Therapeutics in the 2nd quarter valued at $29,000. SVB Wealth LLC acquired a new position in United Therapeutics in the 1st quarter valued at $32,000. Geneos Wealth Management Inc. raised its stake in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the last quarter. Brooklyn Investment Group raised its stake in United Therapeutics by 103.2% in the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 98 shares during the last quarter. Finally, WPG Advisers LLC acquired a new position in United Therapeutics in the 1st quarter valued at $60,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $308.75, for a total transaction of $3,396,250.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares in the company, valued at approximately $11,356,133.75. This represents a 23.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 322,935 shares of company stock valued at $133,361,282. Company insiders own 10.30% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on UTHR shares. Weiss Ratings reissued a “hold (c+)” rating on shares of United Therapeutics in a research note on Wednesday, October 8th. Wells Fargo & Company began coverage on United Therapeutics in a research note on Monday. They issued an “underweight” rating and a $414.00 price objective for the company. UBS Group raised their target price on United Therapeutics from $560.00 to $580.00 and gave the stock a “buy” rating in a research note on Monday, September 29th. Bank of America raised their target price on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 2nd. Finally, Morgan Stanley raised their target price on United Therapeutics from $328.00 to $435.00 and gave the stock an “equal weight” rating in a research note on Friday, October 10th. Nine equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $461.62.

United Therapeutics Stock Up 1.1%

Shares of UTHR opened at $426.21 on Friday. The company has a market capitalization of $19.23 billion, a PE ratio of 16.64, a price-to-earnings-growth ratio of 4.60 and a beta of 0.66. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $459.48. The stock has a fifty day simple moving average of $395.28 and a two-hundred day simple moving average of $331.38.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). The business had revenue of $798.60 million for the quarter, compared to analysts’ expectations of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business’s revenue for the quarter was up 11.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.85 earnings per share. As a group, equities analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.